Loading...
Loading...
CBIO| Name | Value |
|---|---|
| Revenues | 0.0K |
| Cost of Revenue | 0.0K |
| Gross Profit | 0.0K |
| Operating Expense | 5,166.0K |
| Operating I/L | -5,166.0K |
| Other Income/Expense | 282.0K |
| Interest Income | 283.0K |
| Pretax | -4,884.0K |
| Income Tax Expense | -282.0K |
| Net Income/Loss | -4,602.0K |
Catalyst Biosciences, Inc. is a clinical-stage biopharmaceutical company specializing in developing protease product candidates for hemostasis and complement regulation. Its protease engineering platform creates improved or novel molecules to address diseases resulting from complement system dysregulation. The company's product pipeline includes CB 2782-PEG and CB 4332 for the treatment of dry age-related macular degeneration (dAMD) and deficiencies in complement factor I (CFI), respectively. Additionally, it develops ProTUNE C3b/C4b degrader and ImmunoTUNE C3a/C5a degrader platforms targeting complement and inflammatory pathway disorders. Catalyst Biosciences, Inc. generates revenue through strategic research collaborations and license agreements with industry partners.
